Cytos Says Allergy Drug Meets Main Target in Study – Reuters

 Cytos says allergy drug meets main target in study   Reuters
Cytos says allergy drug meets main target in study
Reuters
ZURICH, July 31 (Reuters) – An allergy treatment from Swiss biotech company Cytos (CYTN.S) met its main target in a mid-stage trial, the group said on
DGAP-News: Cytos Biotechnology AG: CYT003-qbg10 monotherapy for Ad-Hoc-News (Pressemitteilung)

all 5 news articles »


Comments are closed.